BioSpace News Archive

Arrowhead Pharmaceuticals, Inc. presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe hypertriglyceridemia.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, presented results from the exploratory CMR imaging substudy of ATTRibute-CM, its Phase 3 trial of acoramidis in ATTR-CM.

Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, shared the full data from two posters highlighting advancements across two distinct modalities presented at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10 in San Diego, CA.

Regeneron Pharmaceuticals, Inc. announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma at the American Association for Cancer Research Annual Meeting 2024 in San Diego.

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines, announced the publication of positive safety, immunogenicity, and efficacy data from the full cohort of patients enrolled in its GT-30 clinical trial in Nature Medicine.

Edgewood Oncology announced the publication of new preclinical data from a study of BTX-A51 in human liposarcoma conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School to be presented at the AACR Annual Meeting 2024 in San Diego.

Alnylam Pharmaceuticals, Inc. announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic, calcium channel blocker or angiotensin receptor blocker.

Medtronic plc, a global leader in healthcare technology, announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement, were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Session and simultaneously published in The New England Journal of Medicine.

Replimune Group, Inc. announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants, by Michael R. Midgen, M.D., of the University of Texas MD Anderson Cancer Center during an oral session at the AACR 2024 Annual Meeting in San Diego.

Ascentage Pharma announced that it releases the latest results from three preclinical studies of its novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and embryonic ectoderm development inhibitor APG-5918, at the 2024 American Association of Cancer Research Annual Meeting.